ICRA Assigns Credit Rating for Bliss GVS Pharma Limited Instruments
ICRA Limited has assigned credit ratings for the instruments of Bliss GVS Pharma Limited, according to a rating action reported on April 08, 2026.The rating assessment covered the company's fund-based and non-fund-based facilities, spanning both long-term and short-term instruments.
The details of the rated amounts and the corresponding ratings are presented below:
| Instrument | Rated Amount (Rs. crore) | Rating Action |
|---|---|---|
| Long-term/Short-term - Fund-based/Non-fund-based facilities | 100 | [ICRA]A-(Stable)/ assigned |
| Total | 100 |
In a separate rating summary provided by ICRA, the assigned rating for Long term/Short term - Fund-based/Non-fund based facilities totaling Rs. 100 crore was noted as [ICRA]A-(Stable)/ [ICRA]A2+; assigned.
For bank limits rated by ICRA on a Long-Term and Short-Term scale, the following details were provided:
| Details of Bank Limits Rated by ICRA | Amount (Rs. crore) | Rating | Rating Assigned On |
|---|---|---|---|
| Fund/Non Fund- based Limits (Federal Bank Limited) | 100.00 | [ICRA]A- (Stable)/ [ICRA]A2+ | April 07, 2026 |
| Total | 100.00 |
These assigned ratings are specific to the terms and conditions of the instruments. The rating(s) will be due for surveillance within one year from the date of the rating communication letter. ICRA reserves the right to review and/or revise the ratings at any time based on new information or other circumstances.
BLISSGVS Stock Price Movement
Today, Bliss GVS Pharma Limited shares edged higher to close at ₹252.51, gaining 6.99% in post-market trading. The stock rallied strongly, hitting its 52-week high and drawing substantial interest on a volume of 2.71 million shares.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.